Single-cell Genomics Drive Fluidigm's Q2 Revenues up 36 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Fluidigm's second-quarter revenues increased 36 percent year over year, with growth in both its instruments and consumables sales, the South San Francisco, Calif.-based firm said after the close of the market on Thursday.

For the three months ended June 30, total revenues were $17.5 million, compared to $12.9 million for the second quarter of 2012, and beating the average Wall Street estimate of $15.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.